Zizybeoside II



Compound IDCDAMM02222
Common nameZizybeoside II
IUPAC name2-[3-hydroxy-2-(hydroxymethyl)-6-phenylmethoxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
Molecular formulaC25H38O16

Experimental data

Retention time4.97
Adduct[M+H]+
Actual mz595.223
Theoretical mz595.223
Error1.14
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.1063

Identifiers and class information

Inchi keyBEDWWZCYHCGAKV-UHFFFAOYNA-N
SmilesOCC1OC(OC2C(O)C(OC(OCC=3C=CC=CC3)C2OC4OC(CO)C(O)C(O)C4O)CO)C(O)C(O)C1O
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)10
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)20
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)594.566
Computed dipole moment(dipole)10.604
Total solvent accessible surface area (SASA)836.991
Hydrophobic component of SASA (FOSA)305.613
Hydrophilic component of SASA (FISA)288.558
Pie component of the SASA (PISA)242.82
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1639.52
Number of hydrogen bond donors (donorHB)10
Number of hydrogen bond acceptors (accptHB)27.2
Free energy of solvation of dipole (dip^2/V)0.0685906
Index of cohesive interaction in solids (ACxDN^.5/SA)0.102766
Globularity descriptor (glob)0.80338
Predicted polarizability in cubic angstroms (QPpolrz)48.936
Predicted hexadecane/gas partition coefficient (QPlogPC16)19.395
Predicted octanol/gas partition coefficient (QPlogPoct)46.824
Predicted water/gas partition coefficient (QPlogPw)42.374
Predicted octanol/water partition coefficient (QPlogPo/w)-3.408
Predicted aqueous solubility (QPlogS)-0.837
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.039
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.872
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)18.176
Predicted brain/blood partition coefficient (QPlogBB)-3.623
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)6.502
Predicted skin permeability, log Kp (QPlogKp)-4.062
PM3 calculated ionization potential (IP(ev))9.286
PM3 calculated electron affinity (EA(eV))-0.556
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)-2.138
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)243.863
Number of nitrogen and oxygen atoms (#NandO)16
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
P00915CA1Carbonic anhydrase IT13201SEA
P00918CA2Carbonic anhydrase IIT20401SEA
Q16739UGCGCeramide glucosyltransferaseT14908SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P23975SLC6A2Norepinephrine transporterT21945SwissTargetPrediction
P32320CDACytidine deaminase (by homology)T79027SEA
P15692VEGFAVascular endothelial growth factor AT20761SwissTargetPrediction and SEA
P05230FGF1Acidic fibroblast growth factorT18639SwissTargetPrediction and SEA
P09038FGF2Basic fibroblast growth factorT31621SwissTargetPrediction and SEA
Q9Y251HPSEHeparanaseT47623SwissTargetPrediction and SEA
P55263ADKAdenosine kinaseT91661SEA
Q99808SLC29A1Equilibrative nucleoside transporter 1T13491SEA
O43868SLC28A2Sodium/nucleoside cotransporter 2T94627SEA
P35346SSTR5Somatostatin receptor 5T64830SwissTargetPrediction and SEA
P30874SSTR2Somatostatin receptor 2T53024SwissTargetPrediction and SEA
P31391SSTR4Somatostatin receptor 4T62974SwissTargetPrediction and SEA
P30872SSTR1Somatostatin receptor 1T16633SwissTargetPrediction and SEA
P32745SSTR3Somatostatin receptor 3T13644SwissTargetPrediction and SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P60568IL2Interleukin-2T61698SEA
P16455MGMT6-O-methylguanine-DNA methyltransferaseT24587SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
P09382LGALS1Galectin-1T09544SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q15391P2RY14Purinergic receptor P2Y14T16555SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
Q9UMJ8GBA1Lysosomal acid glucosylceramidaseT63243SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T13201DI0166Glaucoma[ICD-11: 9C61]P00915CA1
T13201DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00915CA1
T20401DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P00918CA2
T20401DI0137Essential hypertension[ICD-11: BA00]P00918CA2
T20401DI0166Glaucoma[ICD-11: 9C61]P00918CA2
T20401DI0175Heart failure[ICD-11: BD10-BD1Z]P00918CA2
T20401DI0214Insomnia[ICD-11: 7A00-7A0Z]P00918CA2
T20401DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00918CA2
T14908DI0242Lysosomal disease[ICD-11: 5C56]Q16739UGCG
T14908DI0257Metabolic disorder[ICD-11: 5C50-5D2Z]Q16739UGCG
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T21945DI0013Acute pain[ICD-11: MG31]P23975SLC6A2
T21945DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P23975SLC6A2
T21945DI0087Chronic pain[ICD-11: MG30]P23975SLC6A2
T21945DI0101Corneal disease[ICD-11: 9A76-9A78]P23975SLC6A2
T21945DI0117Depression[ICD-11: 6A70-6A7Z]P23975SLC6A2
T21945DI0166Glaucoma[ICD-11: 9C61]P23975SLC6A2
T21945DI0264Migraine[ICD-11: 8A80]P23975SLC6A2
T21945DI0301Nicotine use disorder[ICD-11: 6C4A]P23975SLC6A2
T21945DI0308Obesity[ICD-11: 5B80-5B81]P23975SLC6A2
T21945DI0324Pain[ICD-11: MG30-MG3Z]P23975SLC6A2
T21945DI0395Stomach cancer[ICD-11: 2B72]P23975SLC6A2
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T47623DI0020African trypanosomiasis[ICD-11: 1F51]Q9Y251HPSE
T47623DI0310Ocular disease[ICD-11: N.A.]Q9Y251HPSE
T91661DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P55263ADK
T13491DI0030Angina pectoris[ICD-11: BA40]Q99808SLC29A1
T64830DI0108Cushing syndrome[ICD-11: 5A70]P35346SSTR5
T53024DI0108Cushing syndrome[ICD-11: 5A70]P30874SSTR2
T53024DI0122Diagnostic imaging[ICD-11: N.A.]P30874SSTR2
T53024DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P30874SSTR2
T62974DI0087Chronic pain[ICD-11: MG30]P31391SSTR4
T62974DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]P31391SSTR4
T16633DI0108Cushing syndrome[ICD-11: 5A70]P30872SSTR1
T16633DI0395Stomach cancer[ICD-11: 2B72]P30872SSTR1
T13644DI0108Cushing syndrome[ICD-11: 5A70]P32745SSTR3
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T24587DI0369Sarcoma[ICD-11: 2A60-2C35]P16455MGMT
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T63243DI0242Lysosomal disease[ICD-11: 5C56]Q9UMJ8GBA1
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025